Globus Medical Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Dan Scavilla
Chief executive officer
US$4.9m
Total compensation
| CEO salary percentage | 9.90% |
| CEO tenure | 3.1yrs |
| CEO ownership | n/a |
| Management average tenure | 6.1yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Globus Medical, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 11
At US$71.91, Is It Time To Put Globus Medical, Inc. (NYSE:GMED) On Your Watch List?
May 05Globus Medical: Digesting Another Acquisition
Apr 23An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 38% Undervalued
Apr 20There May Be Reason For Hope In Globus Medical's (NYSE:GMED) Disappointing Earnings
Mar 05Globus Medical: Some Caution After Its Deal For Nevro
Feb 16Subdued Growth No Barrier To Globus Medical, Inc.'s (NYSE:GMED) Price
Jan 31Globus Medical Stock: Re-Rated After A Solid Year
Nov 18Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet
Nov 04Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit
Oct 14Globus Medical: A Post Acquisition Analysis
Aug 26
Calculated Initiatives And Innovative Technologies Propel Growth In Medical Equipment Sector
Strategic integration and new product launches aim to increase Globus Medical's market share and future revenue through enhanced offerings.Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors
Jun 28Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Globus Medical: Merger Overhang Lingering
Nov 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Globus Medical Q4 2022 Earnings Preview
Feb 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$186m |
| Dec 31 2024 | US$5m | US$481k | US$103m |
| Sep 30 2024 | n/a | n/a | US$92m |
| Jun 30 2024 | n/a | n/a | US$41m |
| Mar 31 2024 | n/a | n/a | US$67m |
| Dec 31 2023 | US$5m | US$464k | US$123m |
| Sep 30 2023 | n/a | n/a | US$158m |
| Jun 30 2023 | n/a | n/a | US$204m |
| Mar 31 2023 | n/a | n/a | US$201m |
| Dec 31 2022 | US$4m | US$437k | US$190m |
| Sep 30 2022 | n/a | n/a | US$155m |
| Jun 30 2022 | n/a | n/a | US$155m |
| Mar 31 2022 | n/a | n/a | US$142m |
| Dec 31 2021 | US$2m | US$396k | US$149m |
| Sep 30 2021 | n/a | n/a | US$187m |
| Jun 30 2021 | n/a | n/a | US$184m |
| Mar 31 2021 | n/a | n/a | US$122m |
| Dec 31 2020 | US$2m | US$384k | US$102m |
| Sep 30 2020 | n/a | n/a | US$95m |
| Jun 30 2020 | n/a | n/a | US$89m |
| Mar 31 2020 | n/a | n/a | US$148m |
| Dec 31 2019 | US$2m | US$366k | US$155m |
| Sep 30 2019 | n/a | n/a | US$146m |
| Jun 30 2019 | n/a | n/a | US$143m |
| Mar 31 2019 | n/a | n/a | US$150m |
| Dec 31 2018 | US$2m | US$355k | US$156m |
Compensation vs Market: Dan's total compensation ($USD4.86M) is below average for companies of similar size in the US market ($USD8.70M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Scavilla (59 yo)
Mr. Daniel T. Scavilla, also known as Dan, is Director since April 03, 2025 at Nevro COrp. He is Director of DENTSPLY SIRONA Inc. from February 5, 2025. He serves as President and Chief Executive Officer a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 22.3yrs | US$3.06m | 16.46% $ 1.3b | |
| President | 3.1yrs | US$4.86m | no data | |
| CFO & COO | 5.8yrs | US$2.36m | 0% $ 0 | |
| Executive VP | 6.4yrs | US$1.63m | 0% $ 0 | |
| Senior Vice President of Business Development & Investor Relations | no data | no data | no data |
Experienced Management: GMED's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 22.3yrs | US$3.06m | 16.46% $ 1.3b | |
| President | 3.1yrs | US$4.86m | no data | |
| Independent Director | 13.8yrs | US$441.52k | 0.026% $ 2.1m | |
| Independent Director | 1.7yrs | US$466.90k | 0.012% $ 918.7k | |
| Independent Director | 6yrs | US$411.52k | 0% $ 0 | |
| Independent Director | 9.8yrs | US$421.52k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$411.52k | 0.018% $ 1.4m | |
| Independent Director | 5.4yrs | US$411.52k | 0.0015% $ 118.1k | |
| Independent Director | 22.2yrs | US$421.52k | 0.51% $ 40.4m | |
| Independent Director | 1.7yrs | US$411.52k | 0.012% $ 968.2k | |
| Independent Director | 14.1yrs | US$421.52k | 0% $ 0 |
Experienced Board: GMED's board of directors are considered experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 10:51 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Globus Medical, Inc. is covered by 26 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Matthew Miksic | Barclays |
| Craig Bijou | BofA Global Research |